HRMY

Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on developing and commercializing therapies for rare neurological disorders. Headquartered in Plymouth Meeting, Pennsylvania, the company specializes in treatments that address significant unmet medical needs in neurology. Harmony's flagship product is WAKIX (pitolisant), the first and only FDA-approved medication with a unique mechanism of action for treating excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company commercializes WAKIX in the United States following its 2019 acquisition of the U.S. rights from Bioprojet Pharma. Beyond narcolepsy, Harmony maintains a pipeline of product candidates targeting additional rare neurological conditions, including Prader-Willi syndrome and myotonic dystrophy. The company operates with a specialized commercial infrastructure designed to serve the rare disease community, employing approximately 300 people. Harmony went public in August 2020 through an initial public offering on the Nasdaq Global Select Market. Recent developments include the company's continued expansion of WAKIX's market penetration and ongoing clinical trials evaluating pitolisant for other indications. Harmony generated $502 million in net product sales in 2023, demonstrating strong commercial execution. The company's business model centers on in-licensing or acquiring rights to novel compounds, conducting clinical development, and building specialized commercial capabilities to serve healthcare providers and patients in the rare disease space.